Surmodics Inc. (SRDX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
SRDX Chart
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates
SurModics (SRDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $0.27 per share a year ago.
Surmodics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| VT Vincent Tortorella Point72 (DIFC) Ltd | 2,526 | $75,502 | $75,502 | - | - |
 Guillaume Binnendijk Cigogne Management SA | 78,500 | $3.11M | $3.11M | - | - |
Surmodics Inc. (SRDX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Surmodics Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Gary R. Maharaj CEO | NASDAQ (NGS) Exchange | 868873100 CUSIP |
| US Country | 389 Employees | - Last Dividend | 7 Dec 2000 Last Split | 4 Mar 1998 IPO Date |
Overview
Surmodics, Inc., along with its subsidiaries, is a pioneering company specializing in performance coating technologies for intravascular medical devices and the supply of crucial chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Its presence is not only strong in the United States but extends internationally, showcasing its global reach and influence in the medical and diagnostic fields. Since its inception in 1979, Surmodics has been headquartered in Eden Prairie, Minnesota, marking its long-standing contribution to the medical technology sector. The company operates through two primary segments: Medical Device and In Vitro Diagnostics (IVD), each focusing on distinct yet interrelated areas of expertise within the medical technology industry.
Products and Services
- Medical Device Segment
- In Vitro Diagnostics (IVD) Segment
This segment of Surmodics is dedicated to enhancing the performance of intravascular medical devices through surface modification coating technologies. These technologies aim to improve access, deliverability, and predictable deployment of various medical devices. Additionally, the segment specializes in drug-delivery coating technologies designed for site-specific drug delivery from the surface of a device, catering to several markets including neurovascular, peripheral, coronary, and structural heart. The manufacturing side of this segment produces vascular intervention medical devices like drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths, further demonstrating Surmodics' comprehensive approach to medical device innovation.
Surmodics' IVD segment concentrates on the development, manufacture, and sale of chemical and biological components essential for in vitro diagnostic immunoassay and molecular tests. This segment supports both diagnostic and biomedical research markets, offering a range of products including protein stabilizers, substrates, surface coatings, and antigens. Through its contributions, the IVD segment plays a critical role in advancing diagnostic capabilities and research efforts globally, highlighting Surmodics' commitment to improving health care through innovation.
